Tyrosine Kinases / Adaptors
SOCS3 Antibody
|
イイネ!(3)
|
|
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報  カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #2923S | 100 μL | 46,000 | |
|
SOCS3抗体製品一覧
2923 の推奨プロトコール
最適な結果を得るために:Cell Signaling Technology (CST) 社は、各製品の推奨プロトコールを使用することを強くお薦めいたします。
推奨プロトコールはCST社内試験の徹底的なバリデーションに基づいて作成されておりますので、正確かつ再現性の高い結果が得られます。
注:各製品に最適化されたプロトコールをリンクしています。
| | |
-
2923:
-
Western Blotting
| 用途(希釈倍率) | |
| ウエスタンブロッティング(1:1,000) |
| 特異性・感度 | |
| 内在性レベルのSOCS3 タンパク質を検出します。 |
| 使用抗原 | |
| SOCS3 タンパク質のLys195 周辺領域(合成ペプチド) |
Western Blotting

Western blot analysis of extracts from various cell lines using SOCS3 Antibody.
The SOCS (suppressor of cytokine signaling) family members are negative regulators of cytokine signal transduction that inhibit the Jak/Stat pathway (1-3). The SOCS family consists of at least 8 members including the originally identified protein CIS1 (cytokine-inducible SH2-containing protein) as well as SOCS1 through SOCS7. Each SOCS family member contains a central SH2 domain and a conserved carboxy-terminal motif designated as the SOCS box. These proteins are important regulators of cytokine signaling, proliferation, differentiation and immune responses.
Low levels of SOCS3 are observed in lung, spleen and thymus, and like other SOCS family members levels its expression is rapidly induced by a number of factors including interleukins, EPO, IFN-γ, CSF and TNF-α (4). SOCS3 uses its SH2 domain to bind activated Jaks and their cognate receptors to provide negative feedback inhibition. In addition to the initially described inducers of SOCS3 expression, subsequent studies have described SOCS3-mediated negative feedback inhibition for leptin (5), GH (6), chemokine receptors (7), insulin (8) and certain pathogens (9,10). SOCS3 deletion results in embryonic lethality with placental insufficiency (11). SOCS3 signaling has been linked pathologically to allergic responses (12), inflammatory disease (13), endotoxic shock (14), wound repair (15), and obesity (16,17).
-
Alexander, W.S. et al. (1999) J Leukoc Biol 66, 588-92.
-
Chen, X.P. et al. (2000) Immunity 13, 287-90.
-
Hilton, D.J. et al. (1998) Proc Natl Acad Sci USA 95, 114-9.
-
Starr, R. et al. (1997) Nature 387, 917-21.
-
Bjørbaek, C. et al. (1998) Mol Cell 1, 619-25.
-
Adams, T.E. et al. (1998) J Biol Chem 273, 1285-7.
-
Soriano, S.F. et al. (2002) J Exp Med 196, 311-21.
-
Emanuelli, B. et al. (2000) J Biol Chem 275, 15985-91.
-
Stoiber, D. et al. (1999) J Immunol 163, 2640-7.
-
Stoiber, D. et al. (2001) J Immunol 166, 466-72.
-
Roberts, A.W. et al. (2001) Proc Natl Acad Sci USA 98, 9324-9.
-
Seki, Y. et al. (2003) Nat Med 9, 1047-54.
-
Shouda, T. et al. (2001) J Clin Invest 108, 1781-8.
-
Fang, M. et al. (2005) Cell Mol Immunol 2, 373-7.
-
Goren, I. et al. (2006) J Invest Dermatol 126, 477-85.
-
Mori, H. et al. (2004) Nat Med 10, 739-43.
-
Howard, J.K. et al. (2004) Nat Med 10, 734-8.